Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia (LABMI)
B Acute Lymphoblastic Leukemia, Leukemia Relapse
![University Hospital, Angers](https://trials-media.s3.amazonaws.com/orgs/university-hospital-angers.jpeg)
About this trial
This is an interventional other trial for B Acute Lymphoblastic Leukemia focused on measuring B acute lymphoblastic leukemia, leukemia relapse, pediatric onco-hematology
Eligibility Criteria
Inclusion Criteria for relapse Group :
- Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis
- Obtention of oral and written consent of the parents
- Parents affiliated with the social security system
Inclusion Criteria for control Group :
- Children aged from 1 to 18 years enrolled into FRALLE or EORTC treatment protocols, treated for B-ALL and who are in complete molecular remission
- Obtention of oral and written consent of the parents
- Parents affiliated with the social security system
Exclusion criteria for control Group are the same as for relapsed Group :
- Children with hematologic syndrome predisposing to hematologic neoplasia (such as Fanconi's anaemia, Diamond Blackfan anaemia …) or acute leukemia secondary to previous treatment, or who have had allogenic hematopoietic stem cell transplantation before relapse
Sites / Locations
- University Hospital of Amiens
- University Hospital of Angers
- University Hospital of Besancon
- University Hospital of Bordeaux
- University Hospital of Caen
- Civil Hospices of Lyon
- University Hospital of Marseille
- University Hospital of Nancy
- University Hospital of Nantes
- University Hospital of Nice
- University Hospital of Trousseau (Paris)
- University Hospital of Robert Debre (Paris)
- University Hospital of Reims
- University Hospital of Rennes
- University Hospital of Saint Etienne
- University Hospital of Strasbourg
- University Hospital of Toulouse
- University Hospital of Tours
Arms of the Study
Arm 1
Arm 2
Other
Other
Relapse Group
Control Group
Collection of blood samples will be done in newly diagnosed relapse of B-ALL children at the time of relapse diagnosis. Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis.
Collection of blood samples will be done at the same stage of treatment as the relapse group has been collected. Children aged from 1 to 18 years enrolled into FRALLE (protocol of treatment) or EORTC (European Organisation for Research and Treatment of Cancer) treatment protocols, treated for B-ALL and who are in complete molecular remission. These control patients will be recruited at the same time from the beginning of B-ALL treatment as paired-relapsed control patients.